4/A: Phio Pharma Director Amends RSU Grant Details

Phio Pharmaceuticals Corp. Director Robert L. Ferrara filed an amended Form 4 correcting the number of restricted stock units granted.

Summary

• Robert L. Ferrara, a Director of Phio Pharmaceuticals Corp. (PHIO), filed an amended Form 4.
• The amendment corrects the number of restricted stock units (RSUs) granted on September 11, 2025.
• The original filing incorrectly reported 23,000 RSUs; the correct number granted was 23,100.
• This correction increased the reported beneficial ownership of common stock from 38,666 to 38,766 shares.
• The RSUs represent shares of common stock with a par value of $0.0001 and were granted at a price of $0.
• These RSUs are scheduled to vest on the first annual anniversary of the grant date.
• The reported securities have been adjusted to reflect prior reverse stock splits.

Sentiment

Score: 5

Explanation: The filing is neutral as it is an administrative correction to a previously reported insider transaction, with no material impact on the company's financial or operational outlook.

Positives

• The correction clarifies the exact number of restricted stock units granted to a director, ensuring accurate disclosure.

Negatives

• An initial error in reporting the number of restricted stock units required an amendment, indicating a minor administrative oversight.

Risks

• No specific risks beyond standard market and operational risks inherent to Phio Pharmaceuticals Corp. are detailed in this amendment.

Future Outlook

The 23,100 restricted stock units granted to Director Robert L. Ferrara are scheduled to vest on the first annual anniversary of the grant date, which is September 11, 2026.

Industry Context

This filing is a routine insider transaction report and amendment, providing no specific insights into broader industry trends or competitive landscape for Phio Pharmaceuticals Corp. It reflects standard equity compensation practices for directors.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a common form of executive and director compensation across various industries, aligning interests with shareholders.
• The specific number of units and their value would typically be benchmarked against peer companies in the biotechnology or pharmaceutical sector, though this filing does not provide such comparative data.

Related Party Transactions

• The grant of 23,100 restricted stock units to Robert L. Ferrara, a Director, constitutes a related party transaction as part of his compensation.

Stakeholder Impact

• Shareholders: Minor, as the correction of 100 shares out of 23,100 RSUs is negligible in terms of dilution or ownership structure.
• Director (Robert L. Ferrara): The correction ensures accurate reporting of his equity compensation.

Next Steps

• The restricted stock units granted on September 11, 2025, are expected to vest on their first annual anniversary.

Key Dates

Keywords

Phio Pharmaceuticals, PHIO, Form 4/A, SEC filing, beneficial ownership, restricted stock units, director compensation, equity grant, insider transaction